Previous Page   Next Page

Clinical Data

The efficacy and safety of entrectinib has been studied in phase 1/2 clinical trials (ALKA-372-001, STARTRK-1 and -2, and STARTRK-NG) in adult and paediatric patients, with or without identified NTRK, ROS1 or ALK gene fusions [1-3].

Click on the following links to learn more about the currently available efficacy and safety outcomes from these trials.